HIV/AIDS drug development and treatment

An Optimized Product-Enhanced Reverse Transcriptase Assay for Sensitive and Quantitative Detection of HIV Viral Load and Phenotypic Drug Resistance

This paper introduces an optimized PERT assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance, meeting WHO requirements and enabling faster, more accessible testing.

Forecasting drug resistant HIV protease evolution

The paper develops a probabilistic model to forecast HIV protease drug resistance by simulating evolutionary paths and inferring epistatic interactions from clinical data.

Elucidating the Mechanism by Which HIV-1 Nucleocapsid Mutations Confer Resistance to Integrase Strand Transfer Inhibitors

The paper shows HIV-1 NC mutations accelerate viral DNA integration and reduce INSTI sensitivity, acting with IN mutations to confer resistance.

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to Lenacapavir

This paper investigates how the M66I mutation in HIV-1 capsid protein confers resistance to lenacapavir by altering inhibitor binding and viral replication.

REverse transcriptase ACTivity (REACT) assay for point-of-care measurement of established and emerging antiretrovirals for HIV treatment and prevention

The paper introduces a rapid, portable assay called REACT to measure NNRTIs for HIV treatment and prevention, showing high accuracy in both buffer and plasma samples.

Nucleoside reverse transcriptase inhibitors are the major class of HIV antiretroviral therapeutics that induce neuropathic pain in Mice

This study identifies nucleoside reverse transcriptase inhibitors (NRTIs) as the primary class of antiretrovirals causing neuropathic pain in mice, highlighting their role in peripheral sensory neuropathy.

HIV-1 drug resistance profiling using amino acid sequence space cartography

This paper develops a method using generative topographic mapping to predict HIV drug resistance from genomic data, achieving high accuracy and interpretability.

Molecular Basis for Reduced Cleavage Activity and Drug Resistance in D30N HIV-1 protease

The paper determines the structures of D30N HIV-1 protease with and without nelfinavir, explaining reduced cleavage activity and drug resistance.

Using machine learning and big data to explore the drug resistance landscape in HIV

The paper was withdrawn due to duplicate posting and does not provide original research findings.

Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, northern Tanzania

This study identifies common HIV drug resistance mutations and predictors of virological failure in HIV-infected individuals in Tanzania.

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding

This study uses molecular dynamics simulations to analyze how known drug resistance mutations affect the structure and binding of HIV-1C Integrase with Dolutegravir.

PhyloPi: an affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility

PhyloPi provides an affordable phylogenetic pipeline for HIV drug resistance testing, enabling sample swap detection and genetic diversity analysis using a Raspberry Pi.

sierra-local: A lightweight standalone application for secure HIV-1 drug resistance prediction

sierra-local provides a local, secure alternative to web-based HIV-1 drug resistance prediction tools with high concordance and improved performance.

Structural Adaptation of Darunavir Analogs Against Primary Resistance Mutations in HIV-1 Protease

The paper investigates how structural changes in HIV-1 protease affect the potency of Darunavir and its analogs against primary resistance mutations using crystal structures and vdW interaction analysis.